DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

First Quarter Performance Report
December 29, 2020

Released for Fiscal Year
2020-2021
Continue reading


Notification of Renewal Deadline Extension
December 29, 2020

State Surgeon General Scott A. Rivkees issued Emergency Order 20-015 granting licensure renewal extensions Continue reading